

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Weston, et al.

Confirmation No.: 8629

Serial No.:

10/005,715

Group Art Unit: 1635

Filed:

November 7, 2001

Examiner: J. Schultz

For:

ANTISENSE HUMAN FUCOSYLTRANSFERASE SEQUENCES AND

METHODS OF USE THEREOF

Date: July 23, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the waiver by the U.S. Patent and Trademark Office of requirements under 37 C.F.R. § 1.98(a)(2)(i) for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

/Jarett K. Abramson

Registration No. 47,376

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number: EV 472534629 US

Date of Deposit: July 23, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

Katie A Chung

Myers Bigel Sibley & Sajovec, P.A. P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400

Facsimile: (919) 854-1401

Customer No. 20792

•	<b>1</b>		OIPE
Substitute f	form 1449A/PTO		3
INFORM. STATEM	ATION DISCL	OSURE	
(use as ma	ny sheets as nec	essary)	G TRADEMART
Sheet	В	of	B

Co	omplete if Known	
Application Number	10/005,715	
Filing Date	November 7, 2001	
First Named Inventor	Weston et al.	
Group Art Unit	1635	
Examiner Name	J. Schultz	
Attorney Docket Number	5470-259CT	

			U.S. PATENTS A	AND PATENT PUBLICATIONS	
Examiner Cite No Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
		Number	Kind Code (if known)	Document	MM-DD-YYYY
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner		Name of Patentee or Applicant of Cited	Date of Publication of Cited Document	Т			
Initials*		Document	MM-DD-YYYY				
		<del>  </del>		-			

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т
	1	Abstract 770/ Late Breaker 6, "Fomivirsen Safety and Efficacy in the Treatment of CMV retinitis: A Phase 3, Controlled, Multicenter Study Comparing Immediate Versus Delayed Treatment", http://www.retroconference.org/abstracts/abstracts/LateBreakers/lb6.htm, 8/6/2001, 1 page.	
	2	Galderisi et al., "Antisense Oligonucleotides as Therapeutic Agents", Journal of Cellular Physiology 181:251-257 (1999), 7 pages.	
	3	Burkhart et al., "Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma", Journal of the National Cancer Institute, Vol. 95, No. 18, September 17, 2003, 11 pages.	
	4	Geary et al., "Pharmacokinetics of a Tumor Necrosis Factor- α Phosphorothioate 2'-O (2-Methoxyethyl) Modified Antisense Oligonucleotide: Comparison Across Species", Drug Metabolism and Disposition," Page 10 pages.	
-	5	Rudin et al., "Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined with Carboplatin and Etoposide in Patients with Small-Cell Lung Cancer", Journal of Clinical Oncology, 8 pages.	
	6	Smith et al., "Antisenese oligonucleotides to gastrin inhibit growth of human pancreatic cancer", Cancer Letters 135 (1999) 107-112, 6 pages.	

Examiner Signature	Date Considered	
_		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.